Abstract
Keywords
Introduction
Agonists of benzodiazepine (BZD) binding site in GABAA receptors are important classes of drugs used in the treatment or control of some central nervous system (CNS) diseases (1). They act by improving the gamma-aminobutyric acid (GABAA) receptor function in the central nervous system. Agonists of BZD receptors increase the frequency of the opening of the chlorine channel in response to GABA action which cause anticonvulsant, anxiolytic, sedative and muscle relaxant effects (2-6). In spite of their quick onset of action and low toxicity, benzodiazepines have some undesirable effects such as sedation, negative effect on memory, and development of tolerance to the desirable effects (7). Therefore, the need for novel agonists of benzodiazepine receptors with different chemical and pharmacological structures has been the recent lookout for effective CNS therapy. Our previous studies on BZD receptor ligands showed that some simple non-rigid derivatives with five membered heterocycle rings such as triazoles, oxadiazoles and thiadiazoles had appropriate pharmacological effects (8-15). As shown in Table 1, the Novel 1,3,4-Oxadiazole derivatives were synthetized in order to have selective anticonvulsant or sedative effects with less undesired effects including memory problems (16). In the present study, as an in-vivo model for evaluating BZD effects, elevated plus-maze (EPM), step down passive avoidance and righting reflex tests were performed on novel 2-[2-(2-Chlorophenoxy) phenyl]-1,3,4-oxadiazole derivatives as candidates for agonistic effect on benzodiazepine receptors. To confirm the mode of action of novel compounds, the effect of flumazenil, a BZD receptor antagonist, on the anticonvulsant activity of the compounds has been reported.
Chemical structures of the novel 2-phenoxy phenyl-1,3,4-oxadizole derivatives.
Experimental
Materials and methods
Animals
The animals used for the experiments were male NMRI mice (Pasteur Institute, Iran) weighting in the range of 20-25 g. The animals were housed in a controlled condition and 12 h light/dark cycle. All pharmacological experiments were performed between 9:00 and 15:00. Standard mouse diet and water were freely available to them except during the experiment. Thirty minutes before the experiment, the animals were selected randomly and transferred to individual cages and allowed to acclimatize before injecting drugs or vehicle. This study was performed in accordance with a set of rules approved by the institutional animal care and use committee. All experiments were conducted based on the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and all efforts were made to minimize the number of animals used in the study.
Compounds
As previously described, the novel compounds were synthetized in Shahid Beheshti University of Medical Sciences (16). Flumazenil (Haffman La Rosche), diazepam (Sigma) and sodium pentobarbital (Sigma) were given intraperitoneally (i.p.) as freshly prepared solutions. The novel compounds diazepam and flumazenil were used in a suspension of 1% CMC and 0.5% Tween 80. Pentobarbital was dissolved in water. The injection volume was 10 mL/Kg and the control group was injected with a suspension of 1% CMC and 0.5% Tween 80 (vehicle).
Elevated plus-maze (EPM) test
The elevated plus maze apparatus was made up of Plexiglas and it was consisted of two open arms (30×5×0.5 cm) and two closed arms (30×5×35 cm ) with an open roof. They were arranged so that the open arms were opposite to each other and all the four arms were connected together with a central square of 5×5 cm. The entire maze was elevated at a height of 1 m and was placed inside a light and sound attenuated room (17, 18-20). The mice were placed in the center of the maze facing towards one of the closed arms 30 minutes after intraperitoneal (i.p) administration of test drug or diazepam as standard drug. The number of entries and also the time spent in the open arm were recorded (17). The values for the test compound treated groups were compared with that of the vehicle treated and the standard drug treated groups. In this test, three major parameters were measured including the number of entries in the open and closed arms and the time spent in the open arm of the EPM during a 5 min test session.
Righting reflex test
Righting reflex test was used for the evaluation of hypnotic effect. The test is based on potentiating the pentobarbital induced sleeping time (loss of righting reflex). Thirty min after the administration of novel compounds or diazepam, pentobarbital (40 mg/Kg, ip) was given to induce sleep (21-22). The interval between the loss and recovery of reflex was used as an index of hypnotic effect. The time interval between the injection of pentobarbital and start of losing righting reflex was recorded as latency time. For the compounds with significant hypnotic effects, flumazenil was used to investigate the involvement of benzodiazepine receptors in hypnotic effect of the compounds. Flumazenil was given (10 mg/Kg, i.p.) 15 min before injection of diazepam or novel compounds. Then, the righting reflex test was performed after 30 min.
Step-down passive avoidance test
In the present study, a modification of step-down passive avoidance test was used to assess learning and memory in mice (22). The apparatus (Malek Teb Co., Tehran) consisted of a grid floor with a wooden block (4×4×4 cm) was placed in the center. The block served as a shock free zone. For training trial, each mouse was placed on the wooden platform set in the center of the grid floor. When the mouse stepped down and placed all four paws on the grid floor, the electric shock (0.5 mA, 1 Hz) was given through the grid floor on stepping down. Shocks were delivered for 16 s and the step- down latency (SDL) was recorded. SDL was defined as the time taken by the mouse to step down from wooden platform to grid floor with its entire paw on the grid floor. Mice which showed SDL in the range (2–16 s) during the first test were used for the second session and the retention test (22). Retention test was conducted 24 h later without shock. The time taken for the animal to step down was recorded as step-down latency as a measure of retention. A cut-off time of 300 s was chosen. Novel compounds and diazepam were administered 60 min prior to the training trial. Prolongation of step-down latency was used as a parameter of learning.
Statistical analysis
Statistical analysis of the anxiolytic activity of novel compounds on animals was evaluated using a one-way analysis of variance (ANOVA). In all cases, post-hoc comparisons of the means of individual groups were performed using a Fisher’s Exact Probability test. All values were expressed as mean ± SD (standard deviations). Graph pad Prism software version 5.04 was used for statistical analysis and p < 0.05 was considered statistically significant. Probit-regression method and SPSS software (Chicago, IL; version 13) were used to determine all ED50 values.
Results
Elevated-plus maze test
In the elevated plus maze, the frequency of entries onto the open and closed arms was noted and the time spent on the open arms was measured over 5 minutes. The minimum number of mice in each dose was twelve. In this test, entry onto either arm was counted when the mouse had its body and four paws on the arm. As shown in Table 2, diazepam showed a significant increase in the OAT (open arm time), OAE (open arm entries), TAE (total arm entries) and no effect in the CAE (closed arm entries). There was no significant effect for compounds 1, 2 and 4. Compound 3 had a significant increase on OAE (p < 0.05), CAE (p <0.01) and TAE (p <0.01) which indicated an increase on locomotor activity. Test compounds didn’t show any prominent effect on the time spent on the open arm (OAT).
The results of the elevated-plus maze test on diazepam and the novel 2-phenoxy phenyl-1,3,4-oxadizole derivatives.
| Compound | Dose (mg/Kg) | OATa (s) | OAEb (n) | CAEc (n) | TAEd (n) | Estimated potency (mg/Kg) Mean ± SEM |
|---|---|---|---|---|---|---|
| 1 | 10 | 62.66 ± 23.50 | 2.75 ± 0.52 | 4.75 ± 1.12 | 7.50 ± 1.41 | NDe |
| 20 | 23.50±26.97 | 1.16± 0.42 | 2.16±0.47 | 3.33± 0.81 | ||
| 30 | 66.08±29.40 | 1.25± 0.57 | 3.00± 0.93 | 4.25± 1.14 | ||
| 50 | 73.16±25.55 | 1.58± 0.39 | 1.83± 0.32 | 3.41± 0.55 | ||
| 2 | 10 | 48.33±12.71 | 3.16± 0.53 | 5.85± 0.85 | 5.58± 0.85 | ND |
| 20 | 27.91± 8.45 | 1.83± 0.71 | 4.08± 0.83 | 4.08± 0.85 | ||
| 30 | 61.25± 28.7 | 1.25± 0.41 | 1.83± 0.57 | 1.83±0.57 | ||
| 50 | 92.83± 29.55 | 2.75± 0.67 | 4.5± 1.07 | 4.58± 1.07 | ||
| 3 | 30 | 92.08± 9.40 | 6.66± 1.38 * | 10.50± 1.46 ** | 17.25± 2.62** | ND |
| 50 | 92.41± 26.81 | 4.08± 1.01 | 6.08± 1.22 | 10.16± 2.1 | ||
| 4 | 30 | 58.33± 8.58 | 3.83± 0.51 | 6.5± 0.91 | 10.33± 7.56 | ND |
| 50 | 82.50± 19.50 | 3.75± 0.73 | 6.75± 1.04 | 10.50± 7.02 | ||
| Diazepam | vehicle | 54.00 ±25.03 | 2.0 ± 0.82 | 4.33 ± 0.93 | 6.33 ±1.39 | 0.836 ± 0.130 |
| 0.5 | 63.75 ± 15.85 | 4.5 ± 1.58 | 5.66 ± 1.30 | 10.16 ± 2.7 | ||
| 1 | 123.66 ± 25.94* | 4.91 ± 1.35 | 4.75 ± 1.31 | 9.66 ± 2.37 | ||
| 2 | 182.41 ± 24.51*** | 9.41 ± 1.88* | 4.5 ± 1.15 | 13.9 ± 1.71* |
Righting reflex test
As shown in Table 3, except compound 2, all compounds significantly increased the time of righting test. ED50 was measured for all compounds. The duration of the loss of righting reflex was assessed. The minimum number of mice in each group was twelve. As shown in Table 3, there is a significant difference between diazepam and test compounds.
Effects of diazepam and the novel 2-phenoxy phenyl-1,3,4-oxadizole derivatives on loss of righting reflex.
| Compound | Dose (mg/Kg) | Response (s) | ED50 (mg/Kg) Mean ± SEM | ED50 (mg/Kg) Mean ± SEM (in the presence of flumazenil) | p-valuea |
|---|---|---|---|---|---|
| 1 | Vehicle | 814.17 ± 51.793 | 14.927 ± 1.100 | 68.960 ± 1.069 | p < 0.001 |
| 5 | 946.67 ± 124.570 | ||||
| 10 | 1321.67 ± 101.699* | ||||
| 20 | 1650.00 ± 102.956*** | ||||
| 30 | 2108.33 ± 217.062*** | ||||
| 50 | 2615.00 ± 169.563*** | ||||
| 2 | Vehicle | 814.17 ± 51.793 | NDb | ND | p > 0.05 |
| 5 | 830.00 ± 104.849 | ||||
| 10 | 931.67 ± 89.309 | ||||
| 20 | 868.33 ± 109.527 | ||||
| 30 | 878.33 ± 71.620 | ||||
| 50 | 1117.5 ± 65.41 | ||||
| 3 | Vehicle | 814.17 ± 51.793 | 20.606 ± 1.113 | 54.074 ± 1.095 | p < 0.001 |
| 5 | 798.33 ± 85.222 | ||||
| 10 | 1183.33 ± 81.921 | ||||
| 20 | 1795.00 ± 157.792*** | ||||
| 30 | 1613.33 ± 101.314*** | ||||
| 50 | 2225.00 ± 190.416*** | ||||
| 4 | Vehicle | 814.17 ± 51.793 | 17.338 ± 1.108 | 44.055 ± 1.098 | p < 0.001 |
| 5 | 905.00 ± 77.233 | ||||
| 10 | 1321.67 ± 88.823* | ||||
| 20 | 1891.67 ± 144.347** | ||||
| 30 | 1710.00 ± 150.244* | ||||
| 50 | 2288.33 ± 137.366*** | ||||
| Diazepam | Vehicle | 814.17 ± 51.793 | 0.462 ± 1.115 | 1.430 ± 1.112 | p < 0.001 |
| 0.5 | 1705.83 ± 93.812*** | ||||
| 1.25 | 2654.17 ± 103.554*** | ||||
| 2.5 | 3345.00 ± 112.509*** |
Step-down passive avoidance test
To evaluate the effects of the novel compounds on memory, prolongation of step-down latency was used as a parameter of learning and memory. Results of the step-down passive avoidance test have been shown in Table 4. The results show that none of the novel compounds change the step down latency significantly.
Effects of diazepam and the novel 2-phenoxy phenyl-1,3,4-oxadizole derivatives on step-down latency.
| Compound | Dose (mg/Kg) | Response (s) Mean ± SEM | Estimated potency (mg/Kg) Mean ± SEM | p-valuea |
|---|---|---|---|---|
| 1 | Vehicle | 231.12 ± 10.79 | NDb | p > 0.05 |
| 25 | 233.50 ± 16.35 | |||
| 50 | 227.37 ± 23.44 | |||
| 2 | Vehicle | 231.12 ± 10.79 | ND | p > 0.05 |
| 25 | 244.75 ± 13.93 | |||
| 50 | 216.62 ± 19.84 | |||
| 3 | Vehicle | 231.12 ± 10.79 | ND | p > 0.05 |
| 25 | 236.12 ± 16.96 | |||
| 50 | 193.75 ± 31.12 | |||
| 4 | Vehicle | 231.12 ± 10.79 | ND | p > 0.05 |
| 25 | 225.87 ± 18.58 | |||
| 50 | 207.25 ± 21.18 | |||
| Diazepam | Vehicle | 231.12 ± 10.79 | 3.041 ± 1.479 | p < 0.001 |
| 1 | 175.37 ± 12.88** | |||
| 2 | 136.62 ± 13.03*** |
Discussion
An effective anxiolytic agent should reduce anxiety and exert a calming effect. On the other hand, a hypnotic drug should produce drowsiness and encourage the onset and maintenance of a state of sleep. Hypnotic effects involve more pronounced depression of the central nervous system than sedation and this can be achieved with many BZDs. Many of the common adverse effects of hypnotic agents result from dose-related depression of the central nervous system. Relatively low doses of BZDs may lead to drowsiness, impaired judgment and diminished motor skills. Aside from their quick onset of action and low toxicity, benzodiazepines have some undesirable effects such as sedation, negative effect on cognition, and development of tolerance to the desirable effects. Therefore, synthesis of novel agonists of benzodiazepine receptors with different chemical structure is still an important challenge. In this study, pharmacological evaluation of anxiolytic, sedative-hypnotic and memory impairment effects of the novel compounds and diazepam, as a reference, were tested using three well-known tests (23). Results of righting reflex test clearly indicated that the compounds with NH2, SH, or SCH3 groups on 2-position of 1,3,4-oxadiazole ring have a considerable hypnotic effect. However, their potencies were less than diazepam and there was no significant difference among those of the three compounds. It means the compounds with NH2, SCH3, or SH groups have similar hypnotic effects and compound with OH group on 2-position of the heterocyclic ring did not show hypnotic effect. The hypnotic activities of three compounds as well as diazepam were reduced by flumazenil; it concludes that these effects were mediated through benzodiazepine receptors. All the compounds show no significant effects on memory and anxiety in step-down passive avoidance and elevated-plus maze test respectively. Since the previously reported study showed that the compound with OH substituents on 2-position of 1,3,4- oxadiazole ring (Compound 2) has a considerable anticonvulsant activity (16), Compound 2 might be a valuable lead compound to develop novel potent anticonvulsant agents with no impairment on learning and memory. The observed results in this study are completely compatible with our previous studies on other 1,3,4-oxadiazole and 1,2,4-triazole derivatives. In all investigated heterocyclic derivatives which were introduced as benzodiazepine receptor ligands, the amino substituent at the same position had the best effect on both hypnotic and anticonvulsant activities beside no effect on memory (8-15). The pharmacological relevance of the multitude of structurally diverse GABAA receptor subtypes determines that α1 subunit of the GABAA receptors is responsible for hypnotic activity of BZD agonists and also the effect on memory is mediated through the GABAA receptors with α5 subunit (24). Since novel compounds had hypnotic activity with no effect on memory; it seems that these compounds may have higher affinity for α1 than α5 subunit. However, further studies are needed to prove this hypothesis.
Acknowledgements
References
-
1.
Zarghi A, hamedi S, Tootooni F, Amini B, Sharifi B, Faizi M, Tabatabai SA, Shafiee A. Synthesis and pharmacological evaluation of new 2-substituted-5-{2-[(2-halobenzyl)thio)phenyl}- 1,3,4-oxadiazoles as anticonvulsant agents. Sci. Pharm. 2008;76:185-201.
-
2.
Zarghi A, Hajimahdi Z, Mohebbi S, Rashidi H, Mozaffari S, Sarraf S, Faizi M, Tabatabai SA, Shafiee A. Design and synthesis of new 2-substituted-5-[2-(2-halobenzyloxy)phenyl]-1,3,4-oxadiazoles as anticonvulsant agents. Chem. Pharm. Bull. 2008;56:509-512. [PubMed ID: 18379099].
-
3.
Guerrini G, Ciciani G, Cambi G, Bruni F, Selleri S, Besnard F, Montali M, Martini C, Ghelardini C, Galeotti N, Costanzo A. Novel 3-iodo-8-ethoxypyrazolo [5, 1- c][1, 2, 4] benzotriazine 5-oxide as promising lead for design of α5-inverse agonist useful tools for therapy of mnemonic damage. Bioorg. Med. Chem. 2007;15:2573-2586. [PubMed ID: 17306981].
-
4.
Zarghi A, Faizi M, Shafaghi B, Ahadian A, Khojastehpoor HR, Zanganeh V, Tabatabai SA, Shafiee A. Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1, 3, 4-oxadiazoles as benzodiazepine receptor agonists. Bioorg. Med. Chem. Lett. 2005;15:3126-3129. [PubMed ID: 15876530].
-
5.
Kyung-Hy H, Endo S, Olsen R. Diazepam-insensitive GABAA receptors in rat cerebellum and thalamus. Eur. J. Pharmacol. 1996;31:225-233.
-
6.
Geoffrey S, Olsen R. Functional domains of GABAA receptors. Trends Pharmacol. Sci. 1995;16:162-168. [PubMed ID: 7624971].
-
7.
Narwal S, Kumari K, Narwal S, Singh G, Singh R, Sarin R. Behavior and pharmacological animal models for the evaluation of learning and memory condition. Indo. Global. J. Pharm. Sci. 2012;2:121-129.
-
8.
Almasirad A, Tabatabai SA, Faizi M, Kebriaeezadeh A, Mehrabi N, Dalvandi A, Shafiee A. Synthesis and anticonvulsant activity of new 2-substituted-5-[2-(2-fluorophenoxy) phenyl]-1, 3, 4-oxadiazoles and 1, 2, 4-triazoles. Bioorg. Med. Chem. Lett. 2004;14:6057-6059. [PubMed ID: 15546729].
-
9.
Zarghi A, Tabatabai SA, Faizi M, Ahadian A, Navabi P, Zanganeh V, Shafiee A. Synthesis and anticonvulsant activity of new 2-substituted-5-(2-benzyloxyphenyl)-1, 3, 4-oxadiazoles. Bioorg. Med. Chem. Lett. 2005;15:1863-1865. [PubMed ID: 15780622].
-
10.
Almasirad A, Vousooghi N, Tabatabai SA, Kebriaeezadeh A, Shafiee A. Synthesis, anticonvulsant and muscle relaxant activities of substituted 1, 3, 4-oxadiazole, 1, 3, 4-thiadiazole and 1, 2, 4-triazole. Acta. Chim. Slovenica. 2007;54:317-324.
-
11.
Faizi M, Ahangar N, Shafaghi B, Shafiee A, Tabatabai SA. Design, synthesis and pharmacological evaluation of novel 2-[2-(2-chlorophenoxy) phenyl]-1, 3, 4-oxadiazole derivatives as benzodiazepine receptor agonists. Iran. J. Pharm. Res. 2012;11:83-90. [PubMed ID: 25317188].
-
12.
Akbarzadeh T, Tabatabai SA, Khoshnoud MJ, Shafaghi B, Shafiee A. Design and synthesis of 4H-3-(2-Phenoxy)phenyl-1,2,4-triazole derivatives as benzodiazepine receptor agonists. Bioorg. Med. Chem. 2003;11:769-773. [PubMed ID: 12538007].
-
13.
Mahdavi M, Akbarzadeh T, Sheibani V, Abbasi M, Firoozpour L, Tabatabai SA, Shafiee A, Foroumadi A. Synthesis of two novel 3-Amino-5-[4-chloro-2-phenoxyphenyl]-4H-1, 2, 4-triazoles with anticonvulsant activity. Iran. J. Pharm. Res. 2010;9:265-269. [PubMed ID: 24363736].
-
14.
Tabatabai SA, Barghi Lashkari S, Zarrindast MR, Gholibeikian M, Shafiee A. Design, synthesis and anticonvulsant activity of 2-(2-phenoxy) phenyl-1, 3, 4-oxadiazole derivatives. Iran. J. Pharm. Res. 2013;12:105-111. [PubMed ID: 24250678].
-
15.
Foroumadi A, Sheibani V, Sakhteman A, Rameshk M, Abbasi M, Farazifard R, Tabatabai SA, Shafiee A. Synthesis and anticonvulsant activity of novel 2-amino-5-[4-chloro-2-(2-chlorophenoxy) phenyl]-1, 3, 4-thiadiazole derivatives. Daru J. Pharm. Sci. 2007;15:89-93.
-
16.
Faizi M, Sheikhha M, Ahangar N, Tabatabaei Ghomi H, Shafaghi B, Shafiee A, Tabatabai SA. Design, synthesis and pharmacological evaluation of novel 2-[2-(2-chlorophenoxy) phenyl]-1,3,4-oxadiazole derivatives as benzodiazepine receptor agonists. Iran. J. Pharm. Res. 2012;11:83-90. [PubMed ID: 25317188].
-
17.
Somani RR, Kadam G, Vohra R, Vijayaraghavan S, Shirodkar PY. Studies of CNS activities of some Mannich bases of 1,3,4-oxadiazole. Int. J. Pharm. 2010;5:696-704.
-
18.
Grasso S, Desarro G, Dessarro A, Zappala M, Demicheli C. Synthesis and anticonvulsant activity of novel and potent 2,3-benzodiazepine AMPA/kinate receptor antgonists. J. Med. Chem. 1999;42:4414-4421. [PubMed ID: 10543885].
-
19.
Fernandes C, File SE. The influence of open arm and maze experience in the EPM, Pharm. Biochem. Behav. 1996;54:34-40.
-
20.
Jones GH, Schneider C, Seidler J, Cole BJ, Stephens DN. Comparison of several benzodiazepine receptor ligands in two model of anxiolytic activity in the mouse. Psychopharmac. 1994;14:191-199.
-
21.
Suleyman H, Guvenalp Z, Kizilkaya M, Demirezer LO, Yakugaku Z. Molecular Mechanism of Learning and Memory Based on the Research for Ca/Calmodulin-dependent Protein Kinase II. Pharm. Soc. Jpn. 2007;127:1173-1190.
-
22.
Vogel GH, Vogel HW. Drug Discovery and Evaluation: Pharmacological Assay. Berlin Heidelberg: Berlin: Springer-Verlag; 1997. p. 27-28.
-
23.
Trevor A, Way W. Sedative-hypnotic drugs. In: Katzung B.G, editor. basic & clinical pharmacology. USA: McGraw; 2004. p. 351-366.
-
24.
Victor C, Loren M, Erin E, John K, Howard M, Franco T, John R, John M, Amit B, Neil C, Keith W, Beverley O. α5 GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate. J. Neurosci. 2006;26:3713-3720. [PubMed ID: 16597725].